Vir Biotechnology, Inc. Operating Income Loss

• Vir Biotechnology, Inc. showed an increase of +18.4% in Operating Income Loss from 2024 to 2025.
• This data is from Vir Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), Vir Biotechnology, Inc.'s Operating Income Loss has declined by 488.2%.
• Historical annual values: Fiscal year 2025: -$479.33 million | Fiscal year 2024: -$587.17 million | Fiscal year 2023: -$684.31 million | Fiscal year 2022: $833.07 million | Fiscal year 2021: $420.75 million | Fiscal year 2020: -$296.98 million | Fiscal year 2019: -$177.98 million | Fiscal year 2018: -$118.69 million | Fiscal year 2017: -$81.50 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026